View all news

    NEW DATA SHOWS STELARA® (USTEKINUMAB) MAINTAINED CLINICAL RESPONSE AND REMISSION AFTER TWO YEARS OF TREATMENT IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

    02/17/2017
    Download(opens in new window)PDF

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com